米国の抗真菌薬市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、剤形別、流通チャネル別、セグメント別予測、2025年～2030年

米国の抗真菌薬市場サマリー

米国の抗真菌薬市場は、2024年に60億5,000万米ドルと推定され、2025年から2030年にかけてCAGR 3.0%で成長し、2030年には72億米ドルに達すると予測されます。真菌感染症の罹患率の増加が市場拡大の原動力となっています。

真菌感染症は、水虫、白癬、膣イースト菌感染症から、カンジダ血症、アスペルギルス症、ムコルミコーシスのような重篤な全身疾患に至るまで、幅広い症状をカバーしています。CDCは、カンジダ・オーリスと耐性アスペルギルス種を深刻な脅威として認識しており、治療法の進歩と感染管理の強化が必要であるとしています。米国の抗真菌薬産業は、主にがん患者、移植患者、HIV感染者などの免疫不全グループにおける真菌感染症の一貫した増加、ICU入院の増加、カテーテルや人工呼吸器などの医療機器の使用の増加によって牽引されています。このような集団は、カンジダ血症やアスペルギルス症などの侵襲性感染症に特に罹患しやすく、全身的な抗真菌治療が必要となります。さらに、爪真菌症や皮膚糸状菌症などの表在性真菌症は依然として蔓延しており、頻繁に再発するため、経口および外用の抗真菌薬に対する安定した需要が維持されています。サーベイランスデータによると、非アルビカンス型カンジダ属は血流感染症の約3分の2を引き起こしており、分離株の6％がフルコナゾールに、2％がエキノカンジンに耐性を示しています。

2024年5月のCDCによれば、毎年7万5,000件以上の入院と900万件近くの外来受診が真菌症に起因しています。2024年4月のデータでは、年間約25,000例のカンジダ症が発生し、患者の約3分の1が入院中に死亡しています。公衆衛生の取り組みは、真菌症に対する意識を着実に高めています。2025年9月に予定されているCDCの真菌症啓発週間は、早期診断の促進と耐性菌サーベイランスの強化を目的としています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の抗真菌薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国の抗真菌薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 米国の抗真菌薬市場：パイプライン分析

第4章 米国の抗真菌薬市場：薬物クラスの推定・動向分析

• 薬物クラスセグメントダッシュボード
• 米国の抗真菌薬市場：薬剤クラスの変動分析
• 米国の抗真菌薬市場規模と動向分析（薬剤クラス別、2018～2030年）
• アゾール
• エキノキャンディン
• ポリエン
• アリルアミン
• その他

第5章 米国の抗真菌薬市場：適応症推定・動向分析

• 適応症セグメントダッシュボード
• 米国の抗真菌薬市場：適応症変動分析
• 米国の抗真菌薬市場規模と動向分析（適応症別、2018～2030年）
• 皮膚糸状菌症
• アスペルギルス症
• カンジダ症
• その他

第6章 米国の抗真菌薬市場：剤形推定・動向分析

• 剤形セグメントダッシュボード
• 米国の抗真菌薬市場：剤形変動分析
• 米国の抗真菌薬市場規模と動向分析（剤形別、2018～2030年）
• 経口薬
• 軟膏
• 粉末
• その他

第7章 米国の抗真菌薬市場：流通チャネル推定・動向分析

• 流通チャネルセグメントダッシュボード
• 米国の抗真菌薬流通チャネル：流通チャネル変動分析
• 米国の抗真菌薬市場規模と動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売店薬局
• その他

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company heat map analysis, 2024
• 企業プロファイル
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Bayer AG
  • Sanofi.
  • Merck &Co., Inc.
  • GSK plc.
  • Abbott.
  • GLENMARK PHARMACEUTICALS INC., USA
  • Enzon Pharmaceuticals, Inc.
  • Astellas Pharma US, Inc.

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 3 U.S. antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 4 U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 5 U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 Financial performance
• Table 7 Key companies undergoing expansions
• Table 8 Key companies undergoing acquisitions
• Table 9 Key companies undergoing collaborations
• Table 10 Key companies launching new products/services
• Table 11 Key companies undergoing partnerships
• Table 12 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. antifungal drugs market: market outlook
• Fig. 10 U.S. antifungal drugs market competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. antifungal drugs market driver impact
• Fig. 16 U.S. antifungal drugs market restraint impact
• Fig. 17 U.S. antifungal drugs market strategic initiatives analysis
• Fig. 18 U.S. antifungal drugs market: drug class movement analysis
• Fig. 19 U.S. antifungal drugs market: drug class outlook and key takeaways
• Fig. 20 Azoles market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Echinocandins market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Polyenes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Allylamines market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 U.S. antifungal drugs market: by indication, movement analysis
• Fig. 26 U.S. antifungal drugs market: indication outlook and key takeaways
• Fig. 27 Dermatophytosis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Aspergillosis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Candidiasis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 U.S. antifungal drugs market: by dosage form, movement analysis
• Fig. 32 U.S. antifungal drugs market: dosage form outlook and key takeaways
• Fig. 33 Oral drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Powders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Other market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 U.S. antifungal drugs market: by distribution channel, movement analysis
• Fig. 38 U.S. antifungal drugs market: distribution channel outlook and key takeaways
• Fig. 39 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 OtherOthers market estimates and forecasts, 2018 - 2030 (USD Million)

U.S. Antifungal Drugs Market Summary

The U.S. antifungal drugs market was estimated at USD 6.05 billion in 2024 and is projected to reach USD 7.20 billion by 2030, growing at a CAGR of 3.0% from 2025 to 2030. The growing incidence of fungal infections drives market expansion.

Fungal infections cover a broad range of conditions, from athlete's foot, ringworm, and vaginal yeast infections to severe systemic diseases such as candidemia, aspergillosis, and mucormycosis. The CDC identifies Candida auris and resistant Aspergillus species as serious threats, necessitating therapeutic advances and enhanced infection control. The U.S. antifungal drugs industry is mainly driven by a consistent increase in fungal infections among immunocompromised groups, such as cancer patients, transplant recipients, and individuals with HIV; a rise in ICU admissions; and the increased use of medical devices such as catheters and ventilators. This population is particularly vulnerable to invasive infections such as candidemia and aspergillosis, which require systemic antifungal treatments. Furthermore, superficial fungal infections such as onychomycosis and dermatophytosis remain widespread and frequently recur, maintaining steady demand for oral and topical antifungal medications. Surveillance data show that non-albicans Candida species cause approximately two-thirds of bloodstream infections, with 6% of isolates resistant to fluconazole and 2% of C. glabrata isolates resistant to echinocandins, highlighting the need for newer and more effective antifungal therapies.

Systemic fungal infections continue to pose a significant healthcare challenge in the U.S. Each year, more than 75,000 hospitalizations and nearly 9 million outpatient visits are attributed to fungal diseases, as per the CDC in May 2024. As per April 2024 data, ab out 25,000 cases of candidemia occur annually, with roughly one-third of patients dying during their hospital stay. Public health initiatives are steadily raising awareness of fungal diseases. The CDC's Fungal Disease Awareness Week, scheduled for September 2025, aims to promote early diagnosis and enhance resistance surveillance.

U.S. Antifungal Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. antifungal drugs market on the basis of drug class, indication, dosage form, and distribution channel:

• Drug Class Outlook (Revenue, USD Billion, 2018 - 2030)
• Azoles
• Echinocandins
• Polyenes
• Allylamines
• Others
• Indication Outlook (Revenue, USD Billion, 2018 - 2030)
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Others
• Dosage Form Outlook (Revenue, USD Billion, 2018 - 2030)
• Oral Drugs
• Ointments
• Powders
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)
• Hospital Pharmacies
• Retails Pharmacies
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug class
  • 1.2.2. Indication
  • 1.2.3. Dosage form
  • 1.2.4. Distribution channel
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class outlook
  • 2.2.2. Indication outlook
  • 2.2.3. Dosage form
  • 2.2.4. Distribution channel
• 2.3. Competitive Insights

Chapter 3. U.S. Antifungal Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Antifungal Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Antifungal Drugs Market: Pipeline Analysis

Chapter 4. U.S. Antifungal Drugs Market: Drug class Estimates & Trend Analysis

• 4.1. Drug Class Segment Dashboard
• 4.2. U.S. Antifungal Drugs Market: Drug Class Movement Analysis
• 4.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Azoles
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. Echinocandins
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Polyenes
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.7. Allylamines
  • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Antifungal Drugs Market: Indication Estimates & Trend Analysis

• 5.1. Indication Segment Dashboard
• 5.2. U.S. Antifungal Drugs Market: Indication Movement Analysis
• 5.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
• 5.4. Dermatophytosis
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Aspergillosis
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Candidiasis
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

• 6.1. Dosage Form Segment Dashboard
• 6.2. U.S. Antifungal Drugs Market: Dosage Form Movement Analysis
• 6.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Dosage Form, 2018 to 2030 (USD Billion)
• 6.4. Oral Drugs
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Ointments
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Powders
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Segment Dashboard
• 7.2. U.S. Antifungal Distribution Channel: Indication Movement Analysis
• 7.3. U.S. Antifungal Drugs Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Billion)
• 7.4. Hospital Pharmacies
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.5. Retails Pharmacies
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Novartis Pharmaceuticals Corporation
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Bayer AG
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Sanofi.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Merck & Co., Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. GSK plc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Abbott.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. GLENMARK PHARMACEUTICALS INC., USA
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Enzon Pharmaceuticals, Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Astellas Pharma US, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives